Novel therapeutics for the treatment of hypertension and its associated complications : peptide- and nonpeptide-based strategies
The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential cellular processes and leads to high blood pressure, oxidative stress, inflammation, fibrosis, and hypertrophy. Consequently, these conditions cause fatal cardiovascular and renal complications. Thus, the primary purpose of hypertension treatment is to diminish or inhibit overactivated RAAS. Currently available RAAS inhibitors have proven effective in reducing blood pressure; however, beyond hypertension, they have failed to treat end-target organ injury. In addition, RAAS inhibitors have some intolerable adverse effects, such as hyperkalemia and hypotension. These gaps in the available treatment for hypertension require further investigation of the development of safe and effective therapies. Current research is focused on the combination of existing and novel treatments that neutralize the angiotensin II type I (AT1) receptor-mediated action of the angiotensin II peptide. Preclinical studies of peptide- and nonpeptide-based therapeutic agents demonstrate their conspicuous impact on the treatment of cardiovascular diseases in animal models. In this review, we will discuss novel therapeutic agents being developed as RAAS inhibitors that show prominent effects in both preclinical and clinical studies. In addition, we will also highlight the need for improvement in the efficacy of existing drugs in the absence of new prominent antihypertensive drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Hypertension research : official journal of the Japanese Society of Hypertension - 44(2021), 7 vom: 15. Juli, Seite 740-755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghatage, Trupti [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
11128-99-7 |
|---|
| Anmerkungen: |
Date Completed 27.12.2021 Date Revised 29.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41440-021-00643-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322885167 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322885167 | ||
| 003 | DE-627 | ||
| 005 | 20231225183005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41440-021-00643-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322885167 | ||
| 035 | |a (NLM)33731923 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghatage, Trupti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel therapeutics for the treatment of hypertension and its associated complications |b peptide- and nonpeptide-based strategies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2021 | ||
| 500 | |a Date Revised 29.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential cellular processes and leads to high blood pressure, oxidative stress, inflammation, fibrosis, and hypertrophy. Consequently, these conditions cause fatal cardiovascular and renal complications. Thus, the primary purpose of hypertension treatment is to diminish or inhibit overactivated RAAS. Currently available RAAS inhibitors have proven effective in reducing blood pressure; however, beyond hypertension, they have failed to treat end-target organ injury. In addition, RAAS inhibitors have some intolerable adverse effects, such as hyperkalemia and hypotension. These gaps in the available treatment for hypertension require further investigation of the development of safe and effective therapies. Current research is focused on the combination of existing and novel treatments that neutralize the angiotensin II type I (AT1) receptor-mediated action of the angiotensin II peptide. Preclinical studies of peptide- and nonpeptide-based therapeutic agents demonstrate their conspicuous impact on the treatment of cardiovascular diseases in animal models. In this review, we will discuss novel therapeutic agents being developed as RAAS inhibitors that show prominent effects in both preclinical and clinical studies. In addition, we will also highlight the need for improvement in the efficacy of existing drugs in the absence of new prominent antihypertensive drugs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bispecific peptides | |
| 650 | 4 | |a Hypertension treatment | |
| 650 | 4 | |a Preclinical and clinical studies | |
| 650 | 4 | |a RAAS | |
| 650 | 4 | |a Target organ damage | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Angiotensin II |2 NLM | |
| 650 | 7 | |a 11128-99-7 |2 NLM | |
| 700 | 1 | |a Goyal, Srashti Gopal |e verfasserin |4 aut | |
| 700 | 1 | |a Dhar, Arti |e verfasserin |4 aut | |
| 700 | 1 | |a Bhat, Audesh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hypertension research : official journal of the Japanese Society of Hypertension |d 1996 |g 44(2021), 7 vom: 15. Juli, Seite 740-755 |w (DE-627)NLM075611406 |x 1348-4214 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2021 |g number:7 |g day:15 |g month:07 |g pages:740-755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41440-021-00643-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2021 |e 7 |b 15 |c 07 |h 740-755 | ||